The story in detail
An early trial investigated oral encapsulated faecal microbiota transplantation in 15 adults with peanut allergy. Some received antibiotics beforehand. Several participants could tolerate a higher peanut exposure before reacting, and researchers examined associated changes in immune cells and bile-acid metabolites. Transferring microbiota from responders into mice also produced a protective pattern.
Combining a human experiment with mechanistic work makes the findings interesting, but the clinical trial was small, open-label and lacked a comparison group. A higher reaction threshold does not mean that an allergy has disappeared or that peanuts can be eaten freely. Controlled studies must establish durability, safety and effectiveness. The research does not replace existing allergy precautions, and microbiota transplantation is not a procedure to attempt at home.
Updated: 20 October 2026 · Study date: 2026-08-05
What was found?
Fifteen people with peanut allergy received capsules containing gut microbes from non-allergic donors. After four months, tolerated peanut amounts increased in three of ten participants without prior antibiotics and three of five given antibiotics.
What does it mean?
Human observations and mouse experiments explored how gut microbes interact with immunity.
Limitations
This small, early study does not establish a cure or a treatment safe for everyone. Larger controlled trials are needed. Do not attempt microbiota transfer, antibiotics or allergen challenges at home.
Sources and review scope
English adaptation of the reviewed Turkish edition. The translation preserves its study population, uncertainty and limitations. It is not an independent new study review. Translation checked: 20 October 2026.
Editorial expansion: 21.10.2026
Keep this story
Feedback to the editor
Only the editor can read this; it is not a public comment. Do not include personal health information.
Sign in to send feedback